NCT01966666 - A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Alzheimer's Disease

Interventions

DRUG

TPI-287 2 mg/m2

2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.

DRUG

TPI-287 6.3 mg/m2

6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.

DRUG

TPI-287 20 mg/m2

20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.

DRUG

Placebo

500mL 0.9% sodium chloride.

Trial Locations (1)

94158

UCSF Memory and Aging Center, San Francisco

All Listed Sponsors

lead

University of California, San Francisco

OTHER